Cystic fibrosis (CF) is a heterogeneous multiorgan disease caused by mutations in the CFTR gene leading to misfolding (and other defects) and consequent dysfunction of CFTR protein. The majority of mutations cause a severe CF phenotype, and people with this condition will require a wide variety of medical interventions and therapies throughout their lives to address the symptoms of their condition. CF affects many different organ systems, but the most serious consequence of the disease is degeneration of lung function due to chronic respiratory infection and colonization of the airways with opportunistic microbial pathogens. Improvements in therapeutics, particularly the effective use of antibiotics, have led to significant gradual increases in life expectancy. There remains, however, a continuing need for newer, safer and more effective antimicrobials and mucolytic agents to maintain and improve our ability to combat CF lung infections before other curative approaches which target the root cause of the disease become available.

**Keywords:** bacterial biofilms • CFTR • cystic fibrosis • lung infection • Pseudomonas aeruginosa • respiratory disease

**Cystic fibrosis**

Cystic fibrosis (CF) is an inherited, multiorgan, multifactorial protein misfolding disease with its major pathologic impact being on respiratory function. Digestive, reproductive and other co-morbidities are also common in CF patients; a life-shortening disease that affects around 1 in 2500 babies of Caucasian ethnicity. Symptoms of the condition vary between individuals, but historically this condition was associated with mortality in infancy. Today, with improvements in the management of the condition, and application of the range of treatments and protocols required for management of the CF patient, many of those affected live into their 40s or beyond. Other factors in improved life expectancies are the recent development of novel, personalized medicinal therapies and advances in transplant surgery such that a child born with CF in the UK today can expect to live into the 5th or 6th decade of their life [1]. Here we discuss the genetic and protein-level basis for cystic fibrosis, current treatments and latest developments in the treatment of this condition.

The vast majority of affected individuals will have a mutation in the CFTR gene, encoded on human chromosome 7. Cystic fibrosis is an autosomal recessive disease but the spectrum and nature of CF symptoms are largely dependent upon the type of mutation(s) and their interactions. It is often described as a heterogeneous genetic disorder and genotyping of CF patients is the basis of tailored genetic counseling, epidemiological studies and the development of personalized medicine (i.e., mutation-specific therapies combined with symptom specific supportive treatments/care). The ‘sweat test’ which determines secreted chloride levels in sweat (abnormal levels being a hallmark of the condition) and antenatal ultrasound are the nonspecific diagnostic approaches currently employed for CF [2].

---

**Douglas Fraser-Pitt** & Deborah O’Neil

1 NovaBiotics Ltd, Cuickshank Building, Craibstone, Aberdeen, AB21 9TR UK

*Author for correspondence: doug@novabiotics.co.uk*
Over 1000 different mutations in the CFTR gene have been associated with cystic fibrosis, but some mutations are more common than others and there are ethnic and regional preponderances. Mutations can be classified by the way they alter the fate of the CFTR protein. There are currently six recognized classes of mutation, and three of the most common are illustrated in Figure 1. The fully functioning wild-type protein is a transmembrane ion channel with two membrane-spanning domains (MSDs) which span the membrane six times. It has two nucleotide binding domains (NBDs) and a regulatory domain (R) and transports chloride (and other anions) along the electrochemical gradient. Mutations of the CFTR gene lead to either misfolding and consequent degradation or dysfunction/alteration of expression of the CFTR protein or can also prevent translation of the CFTR protein.

Protein misfolding of the CFTR results in to a buildup of intracellular chloride ions which is thought to draw in sodium ions and water down electrochemical and osmotic gradients. One theory is that this leads to dehydration of the surface airway fluid and creates the thick, sticky mucous seen in individuals with CF, and that this creates an environment susceptible to colonization with opportunistic pathogens. Although this was the prevailing theory for many years it is likely that defects in CFTR function also have effects on innate immunity at the airway epithelial cell surface. CFTR also transports thiocyanate ions (SCN), which are a key component of the innate immune defense. Thio cyanate and hypothiocyanite (OSCN) are able to react with potentially damaging innate immune mediators and are thereby thought to have a protective role in protecting the lung during inflammation which may be absent in people with CF [3].

CFTR misfolding also impact the digestive and reproductive systems. People with CF can have gastrointestinal symptoms associated with malabsorption of dietary nutrients, particularly fats, due to reduced enzyme secretion in the pancreas. Some of these symptoms can be addressed through diet management and the use of enzyme replacement therapies. In the reproductive system, some men with mutations in CFTR can have bilateral absence of the vas deferens. Although these affected individuals are usually fertile (i.e., they do produce viable sperm) they would require assisted reproductive technologies to reproduce as the vas deferens have usually degraded prior to birth due to clogging with thick mucus. Although these symptoms will have significant impacts on the quality of life of CF patients, it is the lung infections with opportunistic microbial pathogens such as the bacteria Pseudomonas aeruginosa and Burkholderia cepacia and the fungi Aspergillus fumigatus and consequent respiratory degeneration and failure which are the ultimate cause of death in most individuals with CF. Repeated infections over the duration of their lifetime has an impact upon lung capacity and architecture. Improved physiotherapy regimes, infection prevention strategies and antibiotic therapy have had some of the biggest impacts on improved life expectancy, but the ultimate aim as a means to a cure versus treatment would be to restore the functionality of the misfolded CFTR in CF patients.

Class I, II & III mutations & protein folding & function

A wide variety of mutations in CFTR have been characterized which have been linked with the cystic fibrosis phenotype. As described above (Figure 1), these can be categorized based upon the impact of the mutation on the fate of the CFTR protein. People who are homozygous for class I, II and III mutations most often have a severe cystic fibrosis phenotype and some examples of these classes of CFTR mutation are explored here in more detail. Class IV, V and VI mutations often leave some residual CFTR function and therefore have a less severe phenotype.

F508del-CFTR, or delta-F508 (ΔF508), is the most common CFTR mutation leading to cystic fibrosis [4] F508del-CFTR is a class II mutation. A deletion of three nucleotides in the gene leads to the deletion of the phenylalanine residue at position 508 of the polypeptide chain. Although the protein is fully translated, the absence of this phenylalanine residue leads to misfolding of the CFTR protein in the endoplasmic reticulum and the protein is subsequently degraded. Perhaps surprisingly, wild-type CFTR is also subject to some degree of proteasomal degradation at this stage, but a proportion of functioning wild-type CFTR protein makes it to the plasma membrane allowing for normal chloride ion transport, and this is not the case in people homozygous for F508del-CFTR. The cell proteasomal machinery and the action of ubiquitinases were found to be essential for the recognition and rapid degradation of the misfolded F508del-CFTR protein [5]. A chain of ubiquitin molecules, covalently linked together at Lys48, are needed for the recognition of a labeled protein by the cell proteasome. This phenomenon is known as polyubiquitination [6]. One of the therapeutic goals in cystic fibrosis has been to develop drugs which can assist the correct folding of F508del-CFTR to bypass this cellular quality control step and to restore some function.

Class I mutations (such as G542X) are thought to be the genetic basis for as many as 10% of CF cases [7]. This class of mutation is defined as impairing the translation of the protein and is caused by the creation
Figure 1. Class I mutations (such as G542X) lead to the premature termination of CFTR protein translation. Class II mutations include the common F508del (or ΔF508) which lead to the misfolding of CFTR protein and subsequent polyubiquitination and destruction by the cell proteasome. Class III mutations (such as G551D) are also misfolded, but may be transported to the plasma membrane. They are either poorly regulated or nonfunctional and are subsequently degraded by the cell. Class IV mutations lead to a receptor with reduced chloride conductance, whilst class V mutations lead to reduced expression levels of CFTR. Class VI mutations lead to a higher turnover of CFTR at the plasma membrane. Class IV, V and VI mutations lead to a nonclassical or atypical CF phenotype and are not shown.
of premature stop codons leading to the production of truncated proteins and consequently no functioning CFTR at the plasma membrane. In this specific case the codon for glycine residue (G) at position 542 on the polypeptide chain has been mutated from GGA to the stop codon TGA [8].

Class III mutations, such as G551D, also results in some changes to the structure and function of the CFTR protein. This specific mutation is a missense mutation which leads to an aspartate (D) residue at position 551 instead of the amino acid glycine (G). This effectively swaps a small nonpolar amino acid for a negatively charged amino acid. It is the most common specific mutation in this rare class, and results in a severe CF phenotype. Although the CFTR protein is not removed by cellular quality control systems and is trafficked to the plasma membrane, the mutation leads to the abolition of ATP-dependent gating of the ion channel. This means it is much more likely that channel will be in a ‘closed’ conformation when compared with wild-type channels and it leads to impairment in anion conductance [9].

**Unmet medical need – an orphan disease**

Cystic fibrosis is defined as an orphan disease in that it affects fewer than 200,000 individuals in the USA and has a similar incidence elsewhere in the developed world. The US Orphan Drug Act of 1983 and equivalent legislation worldwide (Australia, Japan and Europe predominantly) provides regulatory and commercial incentives to develop treatments for rare/ultrarare diseases to counterbalance the low numbers of patients requiring medicinal treatments. Orphan drug schemes were introduced to address the very low levels of R&D activity in the rare disease area and allowed for the creation and success of a number of highly innovative biotechnology companies who have come to dominate the orphan drug discovery space which ‘big pharma’ shunned until recently in favor of mass-market ‘blockbuster’ drug discovery and development strategies.

Despite the range of medical interventions CF patients depend on to maintain any quality of life, there are a very limited number of targeted, specific CF therapies and there had been very little progress as regards the discovery of new treatments until very recent times. Despite the market incentives orphan schemes provide and a recent resurgence of R&D efforts in this space, CF remains a highly complex, challenging clinical problem to solve and in the absence of a cure, there remains a need to develop more effective, long-term therapeutics to tackle various aspects of the condition; a priority being well-tolerated, resistance-free medicines for treating and preventing infection in the airways of CF patients and as a consequence improving lung function.

In addition to commercial efforts to develop new CF treatments, research into rare diseases (as well as patient support and disease awareness) in the UK is also supported through research councils UK (RCUK) and charitable trusts like the Cystic Fibrosis Trust, and Rare Disease UK (RDUK). Funding supports projects seeking to understand the fundamental mechanisms of CF and molecular epidemiology, from blue-skies research to applied science which target the development of new therapies. Seed funding, such as that provided by the National Organization for Rare Disorders (NORD) in the USA has been used to develop new research ideas into commercial possibilities, which have also been supported by large US charities such as the Cystic Fibrosis Foundation. CF research will continue in both the academic and commercial sectors, but in the commercial sectors many of the recent developments in CF therapeutics have come from smaller biotechnology firms, in line with trends in orphan drug discovery activities overall.

**Current treatment options**

There is no cure for CF, and treatments largely address multiple symptoms and not the underlying cause of the disease (i.e., protein misfolding). There are a wide range of medical interventions required for CF patients (summarized in Table 1) which have to be tailored to the individual patient and which depend on their specific symptoms, disease etiology, age and general health.

The most successful therapeutic intervention in terms of reducing the morbidity and mortality in CF has been the use of antibiotic therapy for the treatment of CF associated lung disease. Inhaled antibiotics such as tobramycin [32] and colistin [33] have had a significant impact on mortality [34]. Inhalation minimises the systemic side effects of long term antibiotic use.

Many of the treatments described above target respiratory symptoms as infection leads to a gradual deterioration in lung function in CF patients. Bilateral lung transplant surgery is only suitable for a limited number of CF patients when their lung function has been badly affected. There is a shortage of donor organs and there are inherent risks with major surgery. CF patients who are evaluated for this procedure would also need to be on anti-rejection medication for life. Antibiotic therapy is often necessary to optimize the surgical outcome, and colonization with certain microbes would preclude surgery.

**Recent developments in treatments which target the underlying causes of CF**

A few recent advances in CF therapies address the underlying causes of CF. Kalydeco™ (Ivacaftor/VX-770;
Table 1. A list of treatments and medical interventions employed to address cystic fibrosis.

| Treatment                        | Frequency       | Target                     | Purpose                                                                 |
|----------------------------------|-----------------|----------------------------|-------------------------------------------------------------------------|
| Physiotherapy                    | Daily†          | Respiratory system         | CPT – to help patients expectorate and improve mucociliary clearance of the airways |
| Enzyme replacement therapy       | Regularly       | Gastrointestinal tract     | Helps overcome some of the problems associated with pancreatic insufficiency |
| PPIs and antiemetics             | As required     | Gastrointestinal tract     | Often used to help in relieving indigestion and stomach pain and also nausea which might be a side effect of other medications |
| Antibiotics                      | As required – regularly | Respiratory system         | To reduce microbial infection and colonization of the lung              |
| Osmotic therapy                  | Daily†          | Respiratory system         | Hypertonic saline is usually nebulized as a sterile saline mist. Mannitol, administered as a dry powder, has also been demonstrated to improve lung function |
| Bronchodilators                  | Regularly       | Respiratory system         | B-adrenergic receptor antagonists (both fast acting and long lasting) are commonly used to open the airways in responsive patients and prior to physiotherapy sessions to help patients expectorate. Anticholinergic drugs are less commonly used |
| Corticosteroids                  | As required     | Respiratory system         | Used to ameliorate inflammation in appropriate patients with acute airway inflammation |
| Nonsteroidal anti-inflammatory drugs | Daily†      | Respiratory system         | There is evidence that long-term use of ibuprofen can help to delay deterioration in lung function over time, and the Cystic Fibrosis Foundation recommend its use |
| Mucolytic agents                 | Daily†          | Respiratory system         | Pulmozyme®, or donase alfa, is a recombinant human DNAse enzyme marketed by Genentech, and is the leading mucolytic agent used by people with CF. Extracellular DNA (human and microbial) is one of the components of the thick sticky mucous found in CF airways. N-acetylcysteine has also been used as a mucolytic agent for its effects on mucin glycoproteins |
| Assisted Reproductive Technologies | Rarely         | Reproductive system        | Can assist men who have bilateral absence of the vas deferens due to mutations on CFTR but no, or mild CF phenotypes. Assisted reproductive technologies such as IVF have also been used in men and women with more severe phenotypes of CF |
| Surgery                          | Once in a lifetime | Respiratory system         | Bilateral lung transplants are an option in some patients with severe lung disease. Transplant surgery doesn’t cure CF (as other organs will still be affected) and it does have considerable risks but it can extend the lives of those people with CF who have very poor lung function and may improve the quality of life for some |

Patients with the most common severe phenotypes will have experienced many if not most of those listed above during the course of their lives. The Cystic Fibrosis Foundation and other bodies assess the evidence of treatment efficacies gathered through Cochrane reviews and other scientific literature to make informed recommendations for CF patients and their support teams [10].

†Daily treatments for those who require them.

CPT: Chest physiotherapy.
Vertex, MA, USA) was approved by the FDA in 2012 as a treatment for people with the CF class III mutation G551D. This rare gating mutation, discussed above, has also been nicknamed the ‘Celtic’ mutation because of its prevalence in NW Europe, with Ireland having the highest prevalence of G551D CF at 5.7% [11]. Ivacaftor ( VX-770), has been demonstrated to improve lung function in people with at least one G551D allele [12]. It is thought that VX-770 directly binds the CFTR protein and alters the regulation of the protein in a phosphorylation-dependent manner, which increases the likelihood that the channel will be in the ‘open’ conformation, therefore restoring some function [13]. Phase III clinical trials have demonstrated a 10.7% increase in forced expiratory volume (FEV1) measurements of lung function in comparison to controls, and an improvement of 14.2% in FEV1 measurements over the course of the trial.

Another Vertex (Boston, USA) compound, lumacaftor (also known as VX-809), is in development as a treatment for the much more abundant F508del-CFTR class II mutation. This compound partially corrects some of the protein misfolding so that some of the protein escapes endoplasmic reticulum-associated degradation and is translocated to the cell surface. In vitro experiments have demonstrated some restoration of chloride transport across the membrane is restored in cells treated with VX-809, and it is thought that this compound works by stabilizing the conformation of membrane-spanning domain 1 (MSD1) [14]. Further in vitro experimental data on lung cells showed that combination of VX-809 with the potentiator VX-770 (Ivacaftor) enhanced chloride transport [15]. Phase Ila clinical trials using lumacaftor alone demonstrated safety and tolerability of the compound, but failed to improve clinical outcomes measured by FEV1, therefore, Phase III clinical trials in 2014 examined treatments with lumacaftor alone and in combination with ivacaftor. Results from this trial were published very recently and demonstrate improvements in treated versus predicted FEV1 of 2.6–4.0% and reduced exacerbation rates [31]. The impact of the drugs in the target patients population seems to be greater on minimizing exacerbations than FEV1 so distinct from the monotherapy approach with ivacaftor alone. A US FDA approval decision for the combination therapy is expected in July 2015. Although it remains to be seen if early intervention with any of the potentiator/corrector therapies will rescue lung function and reduce morbidity in the long term, these treatments do provide hope along with other supportive therapies, treatments that tackle the folding and function of the CFTR protein might extend the lives and reduce morbidity for people living with CF.

Ataluren is another small molecule in development as a potential therapeutic for certain CF genotypes that targets the CFTR. It is being developed by PTC therapeutics and may also be a potential treatment for some people with Duchenne muscular dystrophy and some other rare conditions as it may overcome problems caused by mutations which lead to premature stop codons, (or nonsense mutations) [17]. It is thought to work by forcing the read-through of transcripts of genes containing a nonsense mutation and has been the subject of Phase II clinical trials in adults and children with rare class I mutations of CF such as G542X (described above) which have demonstrated some improvements in chloride transport in sinus membranes and improved some clinical parameters. It is orally bioavailable and has potential to treat a number of genetic conditions caused by nonsense mutations [18].

Other pharmacological therapies are being developed to address the symptoms and altered physiology in CF that results from CFTR misfolding. These include enhancing thiocyanate levels [19] and direct [20,21] or indirect [22,23] methods for supplementing nitric oxide in the lungs (which is reduced in CF patients [24,25]). Some groups are also investigating the possibility of promoting autophagy via pharmacological means, as this is also known to be dysregulated in people with CF [26].

Novel antimicrobials are badly needed in CF, as well as more widely in treating infectious disease, because of the well known problem of microbial resistance to current antibiotics recently addressed in a UK HM Government report chaired by Jim O’Neill [35]. The development of new antibiotics will hopefully increase the range of therapeutic options for CF patients, and those which can be used in combination with other drugs to reduce the development of antibiotic resistance. Combinatorial antibiotic therapy in CF is in development, such as recent clinical trials using inhaled fosfomycin together with tobramycin [36]. Individual or combined therapies which tackle more than one of the consequences of CF, such as co-delivery of DNaseI with Ciprofloxacin [37] could also prove to be successful. Lynovex®, is a compound in clinical development by NovaBiotics Ltd (Aberdeen, UK) and has potential to be used as an adjunct therapy in CF as it has been demonstrated to have antibacterial, antifilm and mucusolytic activities [38]. Also existing antibiotics, such as aztreonam [39] and levofloxacin [40] have been reformulated for inhalation and have been, or are being, re-purposed for use in treating CF lung disease. Inhaled macrolides [41], such as azithromycin, are also being used primarily because of potential anti-inflammatory [42] and anti-virulence [43] properties second-
ary to their well-known antimicrobial activity as this is thought to be less important when many common CF pathogens such as P. aeruginosa are regularly found to be resistant [44].

The therapy candidates currently in development and those recently approved represent important milestones in CF management, but these pharmacological interventions have not yet been demonstrated to be wholly curative. An alternative approach which has been also a focus of research, is gene therapy. In theory, replacing a faulty gene in all the affected cells with a stably expressed healthy gene could be curative for CF lung disease. Obstacles to gene therapy in CF include the heterogeneous genetic nature of the disease, difficulties in transfecting lung tissue, finding suitable and tolerable genetic transfer agents or vectors, and obtaining stable expression of the wt CFTR protein. Although there have been a number of preclinical and a few clinical developments with regards to gene therapy for CF, Cochrane systemic review analysis of the literature do not yet support topical gene therapy as a treatment for CF [27]. Work continues, and one possible vector for use in future topical gene therapy for CF is the lentiviral vector [28]. The potential for genome editing in stem cells used for therapy in CF is also being investigated [29]. The most recent gene therapy clinical trial data examined nebulised liposomal delivery of plasmid DNA into the lungs of CF patients [45]. The results, although described as modest, suggested the stabilisation of lung function in CF patients receiving gene therapy compared with control with a 3.7% improvement in predicted FEV1.

Although limited in number, the new therapeutics under investigation for CF, including those which enable the correct folding of the CFTR protein demonstrate promise for the future. Efforts are being driven largely by the biotechnology and academic sectors from where the required innovation is being derived. As discussed elsewhere, for example by Fanen et al., 2014 [30], customized and combinatorial therapeutics based upon patient genotype, and clinical need will be a major focus of future research and development.

Conclusion

Cystic fibrosis is a rare genetic, orphan disease. The many genetic causes of the condition largely converge by the impact on the expression, or function of, the CFTR protein. Mutations have been categorised into different classes on the basis of how they effect the function of CFTR and the consequences can be mild to severe disease phenotypes. There are ethnic and geographical patterns in the frequency of different mutations, but F508del-CFTR, which causes a severe disease phenotype, is the most common, and is caused by misfolding of the protein channel. CF is a multi-organ disease, but the most serious impact in people with the severe disease phenotype, is on the respiratory system and the increased susceptibility of individuals to colonisation and infection of the airways by bacteria and fungi. The most successful treatments to date have been the use of prophylactic and inhaled antibiotics, which have treated infectious exacerbations, and managed microbial colonisation of the lungs over long periods of time, and helped to delay the progressive loss of lung function over time. Other therapeutics which have been in use for a long time also tackle the symptoms of this condition, such as the use of mucolytics to break up CF sputum. Although there have been steady increases in median mortality for people with CF, over recent decades there were very few new therapies for this condition and none of the standard drug treatments tackled the underlying cause of the disease. Only surgical intervention through transplantation had the capacity to correct the cause of the disease by replacing diseased organs. In the last few years there have been a number of promising developments, including pharmaceutical therapies, termed correctors and potentiators, which can correct misfolding and improve the function of the CFTR and thus target the cause of the condition.

Future perspective

The clinical consequences of the vast majority of CF cases have been well described for decades (although there are still accounts of patients with rare mutations and atypical presentations). The physiological consequences are also now beginning to be understood: Dysregulated ion transportation across epithelial cell layers at various body sites, and the subsequent impact on body secretions is the major contributor to disease phenotype. This understanding has helped us to develop therapeutics which target the underlying cause of the disease (CFTR) and those which tackle the consequences of disease, including mucolytics, antibiotics to address respiratory infections associated with CF and digestive enzyme replacements to supplement the patient’s low secretion levels in the digestive tract.

The impact on CFTR malfunction on all aspects of innate immunity in the lung is still not fully understood or quantified. As this develops over the next few years, therapeutics supporting immunity, or replacing lost components of immunity, might make an impact in the CF field.

Advances in molecular biology have meant that the genetic component of CF is now well catalogued, and genotyping of CF patients is now well established. Our understanding of the impact of protein folding
of CFTR, and potentially other proteins, as well as CF cell biology is still being fully elucidated however. Recent breakthroughs in pharmacological modification of CFTR were made through screening for active compounds, rather than rational design, but further understanding CFTR protein misfolding, cell quality control systems, and ways to modify these might lead to second and third generations of correctors and potentiators of the underlying cause of CF.

Pharmacological interventions which target the cause of CF are a breakthrough but are not curative. Earlier intervention studies in children with CF have yet to be conducted. Although even with new and improved CFTR modifiers, it is highly likely that therapies which tackle the consequences of CF will still be required. Multi-active or combinatorial therapies could tackle both the causes and consequences of CF. The struggle for new and effective antibiotics in the face of antibiotic resistance is also of increasing relevance to CF, where unavoidable chronic antibiotic use encourages resistance development and patients are susceptible to new and emerging pathogens.

Financial & competing interests disclosure
D O’Neil is Chief Executive Officer of NovaBiotics Ltd. D Fraser-Pitt is an employee of NovaBiotics Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References
1 Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur. Respir. J. 29, 522–526 (2007).
2 Goetzinger KR, Cahill AG. An update on cystic fibrosis screening. Clin. Lab. Med. 30(3), 533–543 (2010).
3 Xu Y, Szép S, Lu Z. The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc. Natl. Acad. Sci. USA 106(48), 20515–20519 (2009).
4 Kerem B, Rommens JM, Buchanan JA et al. Science 245, 1073–1080 (1989).
5 Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 83(1), 121–127 (1995).
6 Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J. 19(1), 94–102 (2000).
7 Rogan MP, Stoltz DA, Hornick DB. Cystic fibrosis transmembrane conductance regulator intracellular processing, trafficking and opportunities for mutation-specific treatment. Chest 139, 1480–1490 (2011).
Cystic fibrosis – a multiorgan protein misfolding disease

8 Schloesser M, Arleth S, Lenz U, Bertele RM, Reiss J. A cystic fibrosis patient with the nonsense mutation G542X and the splice site mutation 1717–1. J. Med. Genet. 28, 878–880 (1991).

9 Bompadre SG, Sohma Y, Li M. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR exhibit distinct gating defects. J. Gen. Physiol. 129, 285–298 (2007).

10 Flume PA, O’Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 176(10), 957–969 (2007).

11 Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations – correlation with incidence data and application to screening. Hum. Mutat. 19, 575–606 (2002).

12 Accurso FJ, Rowe SM, Clancy JP et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N. Engl. J. Med. 363(21), 1991–2003 (2010).

13 Eckford PD, Li C, Ramjesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation, but ATP-independent manner. J. Biol. Chem. 287(44), 36639–36649 (2012).

14 Ren HY, Grove DE, De La Rosa O et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain I. Mol. Biol. Cell 24(19), 3016–24 (2013).

15 Van Goor F, Hadida S, Groenenhuis PDJ et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl Acad. Sci. USA 108(46), 18843–18848 (2011).

16 Clancy JP, Rowe SM, Accurso FJ et al. Results of a Phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67(1), 12–18 (2012).

17 Ellen WM, Barton ER, Zhuo J et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87–91 (2007).

18 Pelz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annu. Rev. Med. 64, 407–425 (2013).

19 Chandler JD, Min E, Huang J, Nichols DP, Day BJ. Nebulized thiocyanate improves lung infection outcomes in mice. Br. J. Pharmacol. 169(5), 1166–1177 (2013).

20 Hopkins N, Gunning Y, O’Croinin DF, Laffey JG, McGoughlin P. Anti-inflammatory effect of augmented nitric oxide production in chronic lung injury. J. Pathol. 209(2), 198–205 (2006).

21 Miller CC, Hergott CA, Rohan M, Arsenault-Mehta K, Düring G, Mehta S. Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia. J. Cyst. Fibros. 12(6), 817–820 (2013).

22 Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur. Respir. J. 25(1), 62–68 (2005).

23 Grasemann H, Tullis E, Ratjen F. A randomized controlled trial of inhaled L-arginine in patients with cystic fibrosis. J. Cyst. Fibros. 12(5), 468–474 (2013).

24 Michl RK, Hentschel J, Fischer C, Beck JF, Mainz JG. Reduced nasal nitric oxide production in cystic fibrosis patients with elevated systemic inflammation markers. PLoS ONE 8(11), e79141 (2013).

25 Walker WT, Liew A, Harris A, Cole J, Lucas JS. Upper and lower airway nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and asthma. Respir. Med. 107(3), 380–386 (2013).

26 Luciani A, Villega VR, Esposito S et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell Biol. 12(9), 863–875 (2010).

27 Lee TW, Southern KW. Topical cystic fibrosis transmembrane conductance regulator gene replacement for cystic fibrosis-related lung disease. Cochrane Database Syst. Rev. 1, CD005599 (2013).

28 Griesenbach U, Alton EW. Moving forward: cystic fibrosis gene therapy. Hum. Mol. Genet. 22(R1), R52–R58 (2013).

29 Schwank G, Koo BK, Sassalli V et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 13(6), 653–658 (2013).

30 Faden P, Wohlhuter-Haddad A, Hinzpeter A. Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. Int. J. Biochem. Cell. Biol. 52, 94–102 (2014).

31 Wainwright CE, Elborn JS, Ramsey BW et al. Lumacaftor–ivacaftor in patients with cystic fibrosis homozygous for Phe508del-CFTR. N. Engl. J. Med. 373(3), 220–221(2015).

32 Stephens D, Carey N, Isles A, Levison H, Gold R. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr. Infect. Dis. 2(3), 209–11 (1983).

33 Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 19(6), 831–838 (1987).

34 Ryan G, Singh M, Dwain K. Inhaled antibiotics for long term therapy in cystic fibrosis. Cochrane Database Syst Rev. 3, CD001021 (2011).

35 The Review on Antimicrobial Resistance. Securing new drugs for future generations: the pipeline of antibiotics (2015).

36 Trappnell BC, McColl SE, Kissner D et al. Phase 2 FTI Study Group. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am. J. Respir. Crit. Care Med. 185(2), 171–178 (2012).

37 Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G, Yeo Y. Inhalable antibiotic delivery using a dry powder co-administered with colistin in cystic fibrosis patients with elevated systemic inflammation markers. PLoS ONE 8(11), e79141 (2013).

38 Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur. Respir. J. 25(1), 62–68 (2005).
38 Charrier C, Rodger C, Robertson J et al. Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis. Orphanet. J. Rare Dis. 9, 189 (2014).

39 Gibson RL, Retsch-Bogart GZ, Oermann C et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol. 41(7), 656–65 (2006).

40 Stockmann C, Hillyard B, Ampofo K, Spigarelli MG, Sherwin CM. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Expert Rev. Respir. Med. 9(1), 13–22 (2015).

41 Siekmeier R1, Hofmann T, Scheuch G. Inhalation of macrolides: a novel approach to treatment of pulmonary infections. Adv. Exp. Med. Biol. 839, 13–24 (2015).

42 Cigana C, Nicolis E, Pasetto M, Assel BM, Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun. 350(4), 977–82 (2006).

43 Skindersoe ME, Alhede M, Phipps R et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52(10):3648–63 (2008).

44 Mulet X, Maciá MD, Mena A, Juan C, Pérez JL, Oliver A. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob. Agents Chemother. 53(4):1552–60 (2009).

45 Alton EW, Armstrong DK, Ashby D et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, Phase 2b trial. Lancet Respir Med. doi:10.1016/S2213-2600(15)00245-3 (2015) (Epub ahead of print).